AUA 2024 Insights: "Circulating MicroRNA Profiling for Prediction of Oncological Outcomes in Prostate Cancer Patients Following Radical Prostatectomy"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

AUA 2024 Insights: "Circulating MicroRNA Profiling for Prediction of Oncological Outcomes in Prostate Cancer Patients Following Radical Prostatectomy"

By Insights from AUA 2024 Annual Meeting FEATURING Fumihiko Urabe

79 views

June 17, 2024

Comments 2

APCCC 2026

Fri, Feb 27, 2026

New

ASCO® GU 2025 Insights: The Influence of Boosting Gut Health and Phy…

Insights from 2025 ASCO® GU Annual Meeting

R. Thomas

86 views

Non-Extirpative Management of Upper Tract Urothelial Carcinoma

Daniel Shapiro

23 views

New

ASCO® GU 2025 Insights: ABLE-32 Trial - Evaluating Nadoferogene Fira…

Insights from 2025 ASCO® GU Annual Meeting

N. Shore

68 views

New

ASCO® GU 2025 Insights: Neoadjuvant Durvalumab + Chemo in Operable H…

Insights from 2025 ASCO® GU Annual Meeting

N. Houede

25 views

New

ASCO® GU 2025 Insights: Efficacy and Safety of Nivo/Ipi in Metastati…

Insights from 2025 ASCO® GU Annual Meeting

M. Moussa

27 views

New

ASCO® GU 2025 Insights: Cabozantinib + Nivo + Ipi in 1L aRCC - Final…

Insights from 2025 ASCO® GU Annual Meeting

L. Albiges

28 views

Oncolytic Immunotherapy With Nivolumab for Muscle-Invasive Bladder C…

Moffitt Cancer Center

R. Li

32 views

Controversies With Testosterone Replacement Therapy and Prostate Can…

Mohit Khera

3.4K views

New

My Journey to Partial Gland Ablation of Prostate Cancer

Focal Therapy Society

H. Lepor

142 views

Testosterone Replacement Therapy and Male Fertility

Mohit Khera

3.2K views

Renal Cancer in Horseshoe Kidney

Bernardo Rocco

48 views

Practical Considerations for PSMA-Targeted Therapy in Prostate Cancer

University of Illinois Cancer Center

K. Tawagi, N. Reizine

360 views

Leveraging Precision Oncology to Improve Outcomes in Bladder Cancer

Vanderbilt University Medical Center (VUMC)

A. Tan

100 views

SIU 2024 Insights: Partial Nephrectomy - Open, Laparoscopic or Robot…

Miguel Ramos

158 views

Recommended Imaging Standards for mHSPC in Daily Practice

Advanced Prostate Cancer Consensus Conference (APCCC)

M. Morris

107 views

AUA 2024 Insights: "Oncological Outcomes of Neoadjuvant Degarelix Wi…

Alexander Giesen

53 views

Improving QoL During and After Treatment in Prostate Cancer

Penn Medicine Abramson Cancer Center

C. Chow, R. Kovell

53 views

Total Therapy Considerations in Low-Volume mHSPC: Intensification vs…

Advanced Prostate Cancer Consensus Conference (APCCC)

O. Sartor

224 views

New

ASCO® GU 2025 Insights: Adjuvant Nivo vs. Placebo in High-Risk MIUC …

Insights from 2025 ASCO® GU Annual Meeting

M. Milowsky

55 views

Year in Review: Bladder Cancer - 2024 Insights and Exciting Prospect…

Jason Hafron

225 views

AUTOPLAY

Login

Login

Join VuMedi

AUA 2024 Insights: "Circulating MicroRNA Profiling for Prediction of Oncological Outcomes in Prostate Cancer Patients Following Radical Prostatectomy"

Related Videos

APCCC 2026

ASCO® GU 2025 Insights: The Influence of Boosting Gut Health and Phy…

Non-Extirpative Management of Upper Tract Urothelial Carcinoma

ASCO® GU 2025 Insights: ABLE-32 Trial - Evaluating Nadoferogene Fira…

ASCO® GU 2025 Insights: Neoadjuvant Durvalumab + Chemo in Operable H…

ASCO® GU 2025 Insights: Efficacy and Safety of Nivo/Ipi in Metastati…

ASCO® GU 2025 Insights: Cabozantinib + Nivo + Ipi in 1L aRCC - Final…

Oncolytic Immunotherapy With Nivolumab for Muscle-Invasive Bladder C…

Controversies With Testosterone Replacement Therapy and Prostate Can…

My Journey to Partial Gland Ablation of Prostate Cancer

Testosterone Replacement Therapy and Male Fertility

Renal Cancer in Horseshoe Kidney

Practical Considerations for PSMA-Targeted Therapy in Prostate Cancer

Leveraging Precision Oncology to Improve Outcomes in Bladder Cancer

SIU 2024 Insights: Partial Nephrectomy - Open, Laparoscopic or Robot…

Recommended Imaging Standards for mHSPC in Daily Practice

AUA 2024 Insights: "Oncological Outcomes of Neoadjuvant Degarelix Wi…

Improving QoL During and After Treatment in Prostate Cancer

Total Therapy Considerations in Low-Volume mHSPC: Intensification vs…

ASCO® GU 2025 Insights: Adjuvant Nivo vs. Placebo in High-Risk MIUC …

Year in Review: Bladder Cancer - 2024 Insights and Exciting Prospect…